Skip to content
Peptide research

Livagen

Category
Bioregulators
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic tetrapeptide marketed as a liver bioregulator that enters liver cells and acts on chromatin to support detox and repair. The case rests almost entirely on mechanism and animal data; claims of pain relief and digestive benefits are speculative, with essentially no human trials. No toxicology or pharmacokinetic data exist, and safety data trace mostly to one research group. Not an approved drug in the US; supply is unregulated research material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Livagen is a synthetic 4-amino-acid peptide (Lys-Glu-Asp-Ala) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Classified as a liver bioregulator, it is unique among peptides because it works through epigenetic gene regulation — physically 'unpacking' tightly wound DNA in liver cells and aged immune cells to reactivate genes that become silenced with aging. It also inhibits enzymes that break down enkephalins (natural pain-relieving molecules) without directly activating opioid receptors.

How it works in the body

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that targets liver cells. It penetrates hepatocyte membranes and interacts with chromatin to modulate gene expression involved in detoxification enzymes, protein synthesis, and the balance of inflammatory vs. protective signaling in liver tissue.

Research overview

Livagen research comes almost exclusively from Khavinson's group in St. Petersburg, with no independent replication by Western laboratories. The evidence consists of cell studies on immune cells from elderly donors (ages 75-88), animal models of liver disease, and enzyme inhibition assays. Key findings include: reactivation of age-silenced genes in elderly immune cells by physically unwinding compacted DNA, liver-protective and immune-boosting effects in animal models (with greatest benefit seen in older animals), potent inhibition of enkephalin-degrading enzymes, and restoration of digestive enzyme activity in old rats to near-youthful levels. No human clinical trials are registered on ClinicalTrials.gov. The lack of independent replication and absence of human trial data represent significant limitations — all claims should be considered preliminary until validated by research groups outside the originating laboratory.

Who researches Livagen?

Commonly researched by

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching liver health

    Studied for hepatoprotective effects or liver function support.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.

    High

    PubMed search for 'Livagen' (19 records, none toxicological); no FDA approval record

  • Sustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.

    Theoretical

    PMID 17460203; PMID 18830022 (context only); PMID 25541832 (context only)

  • No pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).

    Moderate

    PubMed search for 'Livagen' — no pharmacokinetic records

  • No reproductive or developmental toxicity assessments have been performed.

    Moderate

    PubMed search for 'Livagen' — no reproductive toxicology records

  • All safety data originate exclusively from the Khavinson research network with no independent Western verification.

    High

    PubMed author/journal distribution across all 19 Livagen records

  • Human oral bioavailability is unknown; laboratory findings suggest resistance to intestinal peptide hydrolysis.

    Moderate

    PMID 16075683

  • No drug interaction studies have been conducted.

    Moderate

    PubMed search for 'Livagen' — no interaction or CYP records

  • Long-term effects of repeated administration are unknown.

    Moderate

    PubMed search for 'Livagen' — no chronic-administration records

  • Commercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.

    High

    No FDA approval or USP monograph for Livagen/KEDA

Interaction summary(8)

Rated by direction with this peptide

  • Active malignancy or concurrent cytotoxic chemotherapy

    CautionTheoretical

    Livagen's defining action is deheterochromatinization and reactivation of ribosomal genes in human cells (PMID 17460203; PMID 12533768) — de-repressing chromatin and raising ribosome biogenesis is a direction of effect that warrants caution in proliferative disease. The same network has applied peptide bioregulators to genomic parameters in ductal breast cancer patients (PMID 28574395), but that is an exploratory cytogenetic study, not an oncology safety study; no oncology safety or chemotherapy co-administration data exist in any species.

    PMID 17460203; PMID 12533768; PMID 28574395

  • Drugs cleared by hepatic CYP450 metabolism (e.g. warfarin, statins, immunosuppressants, antiepileptics)

    CautionTheoretical

    The peptide is reported to alter hepatocyte gene expression and protein-synthesis rhythm (PMID 15926314), so a shift in clearance of narrow-therapeutic-index drugs is conceivable in principle. No effect of Livagen on any CYP isoform or drug transporter has ever been measured, and no specific enzyme-induction or -inhibition claim is supported by the literature.

    PMID 15926314; no published CYP data

  • Opioid analgesics and other opioidergic agents

    SynergisticTheoretical

    Livagen inhibited enkephalin-degrading enzymes in human serum in vitro, more efficiently than Epitalon in the same assay (PMID 12942748), so an additive endogenous-opioid effect is conceivable. No in vivo enkephalin measurement, analgesia model, or opioid co-administration study exists in animals or humans.

    PMID 12942748

  • Hepatotoxic drugs (acetaminophen, methotrexate, isoniazid, amiodarone)

    ProtectiveTheoretical

    KEDA is reported to show hepatoprotective activity in experimental liver-pathology models and to support regeneration in organotypic liver culture (PMID 32362099; PMID 12577697). This is rodent/ex vivo evidence from a single research network with no human data, and must not be treated as license to exceed hepatotoxic drug limits or to skip liver-enzyme monitoring.

    PMID 32362099; PMID 12577697

  • Immunosuppressants (corticosteroids, calcineurin inhibitors, biologics)

    CautionTheoretical

    A Russian-language review attributes immunoprotective as well as hepatoprotective properties to KEDA (PMID 32362099), so opposition to intentional immunosuppression is mechanistically conceivable. The immunoprotective claim is a review-level assertion rather than a controlled immunological experiment, and no co-administration data exist in animals or humans.

    PMID 32362099

  • Other Khavinson short peptide bioregulators (Epitalon/AEDG, Vilon/KE)

    CautionTheoretical

    These peptides were studied side by side and produced overlapping chromatin-decondensation and enkephalinase-inhibition effects (PMID 15085253; PMID 12942748). Taking them together therefore plausibly adds to the same unmeasured epigenetic action rather than providing independent benefit — treated as a caution, not a synergy, because the combined effect is unquantified and unstudied in combination.

    PMID 15085253; PMID 12942748

  • Alcohol and chronic ethanol exposure

    NeutralTheoretical

    No ethanol-specific study of Livagen exists in any species. General hepatoprotection in experimental liver-pathology models and stimulation of hepatocyte protein synthesis (PMID 32362099; PMID 15926314) have been extrapolated to alcohol elsewhere, but that extrapolation is unsupported; no protective effect against ethanol should be assumed, and Livagen must not be treated as offsetting alcohol-related liver injury.

    PMID 32362099; PMID 15926314 (no ethanol-specific data)

  • Routine clinical laboratory monitoring (liver function panels, CBC)

    NeutralTheoretical

    No assay interference has been reported, and none is expected for a tetrapeptide. Given the total absence of human safety data, baseline and periodic LFTs and CBC are the only practical way to detect a problem.

    No published assay-interference reports

Known risks(9)

  • No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.

  • Sustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.

  • No pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).

  • No reproductive or developmental toxicity assessments have been performed.

  • All safety data originate exclusively from the Khavinson research network with no independent Western verification.

  • Human oral bioavailability is unknown; the cited rat study reported weak hydrolysis and resistance to small-intestinal peptide hydrolases.

  • No drug interaction studies have been conducted.

  • Long-term effects of repeated administration are unknown.

  • Commercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.

Drug interactions(5)

  • No formal drug interaction studies have been conducted for Livagen.

    No interaction data available

  • Theoretical concern: As an inhibitor of enkephalin-degrading enzymes, Livagen could theoretically potentiate endogenous opioid peptide effects, though no opioid receptor binding was observed in vitro.

    No interaction data available

  • Theoretical concern: Patients on hepatically metabolized medications should exercise caution given Livagen's hepatic bioregulatory activity, though specific interactions are unstudied.

    No interaction data available

  • Theoretical concern: Concurrent use with other chromatin-modifying agents (e.g., HDAC inhibitors, DNA methyltransferase inhibitors) could have additive or unpredictable epigenetic effects.

    No interaction data available

  • Theoretical concern: Concurrent use with other Khavinson peptides (Epithalon, Vilon, Ovagen) may have additive chromatin effects — no combination studies exist.

    No interaction data available

Research & benefits

Evidence base

Evidence Level
Preclinical only
Total Studies
8
Human Studies
0

All evidence comes from in vitro human cell studies and animal models. No controlled human clinical trials have been conducted or registered. Research originates almost exclusively from Khavinson's group in Russia and Georgia, with no independent Western replication.

Researched for(4)

Rated by confidence in the evidence

  • Chromatin remodeling and epigenetic rejuvenation

    Low

    Consistent in cultured blood cells from older donors, but never tested in living people.

    PMID 12533768; PMID 15085253; PMID 17460203; PMID 16705247

  • Hepatoprotection and liver function restoration

    Speculative

    Based on animal and cell studies only; no human liver trials exist for this peptide.

    PMID 12577697; PMID 15926314; PMID 32362099; ClinicalTrials.gov (0 records for Livagen)

  • Enkephalin preservation (endogenous pain modulation support)

    Speculative

    Single lab test showed enzyme inhibition in serum; no pain or mood studies done.

    PMID 12942748

  • Age-dependent normalization of digestive enzyme activity

    Speculative

    From a single rat study only; no human digestive or clinical data available.

    PMID 16075683

Benefits(4)

  • Chromatin remodeling and epigenetic rejuvenation

    In vitro studies on lymphocytes from elderly humans (ages 75-88) showed decondensation of pericentromeric and telomeric heterochromatin, reactivation of ribosomal genes, and release of age-repressed genes (Khavinson et al., 2002; Lezhava et al., 2007).

  • Hepatoprotection and liver function restoration

    Animal models of liver fibrosis, acute hepatitis, and chronic hepatitis demonstrated restoration of liver function, normalized immune and antioxidant status, with maximum hepatoprotective effects in aging animals (Kuznik et al., 2020).

  • Enkephalin preservation (endogenous pain modulation support)

    In vitro enzyme assays showed Livagen inhibits enkephalin-degrading enzymes from human serum more potently than puromycin and leupeptin (IC50 ~20 µM), without binding mu- or delta-opioid receptors (Kost et al., 2003).

  • Age-dependent normalization of digestive enzyme activity

    Two-week oral administration in rats showed enzyme activity normalization in old animals to levels approaching young controls, with tissue-specific and age-dependent effects (Timofeeva et al., 2005).

Key studies(7)

  1. Effects of Livagen peptide on chromatin activation in lymphocytes from old people

    In vitro (human lymphocytes)Lymphocyte cultures from elderly donors (ages 75-88)Acute exposure

    Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu

    Bulletin of Experimental Biology and Medicine

    2002

    Livagen caused de-heterochromatinization of chromatin, activating ribosomal genes, inducing decondensation of pericentromeric structural heterochromatin, and releasing genes repressed due to age-related chromatin condensation.

  2. Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK

    Advances in Gerontology

    2020

    Both the liver polypeptide complex (Ventvil) and KEDA tetrapeptide demonstrated high efficacy in restoring liver function in models of fibrosis, acute hepatitis, and chronic hepatitis, normalizing immune and antioxidant status with maximum hepato- and immunoprotective effects observed in aging animals.

  3. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum

    In vitro (human serum enzymes)Enzyme assays with human serumAcute exposure

    Kost NV, Sokolov OYu, Gabaeva MV, Zolotarev YuA, Malinin VV, Khavinson VKh

    Izvestiia Akademii Nauk. Seriia Biologicheskaia

    2003

    Livagen inhibited enkephalin-degrading enzymes from human serum with IC50 of 20 µM, proving more efficient than known peptidase inhibitors (puromycin, leupeptin). No interaction with mu- or delta-opioid receptors was observed.

  4. Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV

    Advances in Gerontology

    2005

    Livagen produced age-dependent effects on digestive enzyme activity: decreasing activity in young rats while increasing it in old rats, with enzyme levels in old animals approaching those of young controls after treatment.

  5. Tissue-specific action of peptides in tissue culture of rats of various ages

    In vitro (rat tissue cultures)Organ-typical cultures from rats of various agesAcute exposure

    Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI

    Advances in Gerontology

    2002

    Livagen and other synthetic peptide bioregulators exerted tissue-specific effects in organ-typical cultures, with selective actions depending on tissue type across different ages.

  6. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals

    In vitro (human lymphocytes)Lymphocyte cultures from elderly donorsAcute exposure

    Lezhava T, Jokhadze T

    Annals of the New York Academy of Sciences

    2007

    Livagen and cobalt ions induced deheterochromatinization of both pericentromeric and telomeric heterochromatin regions in lymphocytes from elderly individuals.

  7. Epigenetic modification under the influence of peptide bioregulators on the 'old' chromatin

    In vitro study of human lymphocyte culturesLymphocyte cultures from donors aged 75–88

    Lezhava T, Jokhadze T, Monaselidze J, et al.

    Georgian Medical News

    2023

    Cell-culture study reporting selective chromatin changes after exposure to several peptide bioregulators, including Livagen; clinical benefit was not tested.

Regulation & availability

Why researchers look at it

In vitro studies on immune cells from elderly donors (ages 75-88) showed this tetrapeptide physically unpacked compacted DNA and reactivated genes silenced by aging — suggesting a direct epigenetic rejuvenation mechanism. However, all ~8 published studies originate from a single Russian laboratory group, with zero registered human clinical trials and no independent Western replication. Until these epigenetic reprogramming claims are validated by outside research groups, Livagen remains one of the most speculative entries in peptide research.

Estimated cost
$30-80/mo oral capsules
FDA status
Not FDA-approved. No Investigational New Drug (IND) application filed. Not listed in any FDA drug database. No clinical trials registered on ClinicalTrials.gov. The peptide lacks an ATC (Anatomical Therapeutic Chemical) code and has no CAS registry number. Not approved by the EMA or any other major Western regulatory body.
WADA status
Livagen is not specifically named on the 2026 WADA Prohibited List. S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no subsequent section applies, regardless of demonstrated performance enhancement. Livagen's product-specific status requires anti-doping confirmation.
Prescribability
No — Livagen is not approved by any major Western regulatory agency (FDA, EMA) and is not a licensed pharmaceutical.
Availability
Livagen is not approved as a pharmaceutical in any major Western jurisdiction. It has a history of clinical use in some Eastern European settings where Khavinson peptide bioregulators are used, and it appears in dietary supplement markets in some jurisdictions with less stringent regulation. The liver polypeptide complex Ventvil (containing KEDA among other peptides) has been used clinically in Russia, but the synthetic KEDA tetrapeptide itself lacks separate pharmaceutical registration.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(8)

  1. Late 1990s
    Livagen (KEDA tetrapeptide) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of the bioregulatory peptide research program.
  2. 2002
    First published studies on Livagen's chromatin activation effects in elderly lymphocytes and tissue-specific action in rat organ cultures.
  3. 2003
    Publication of enkephalin-degrading enzyme inhibition study demonstrating Livagen's IC50 of 20 µM.
  4. 2005
    Publication of digestive enzyme normalization study in rats of different ages.
  5. 2007
    Study on pericentromeric and telomeric heterochromatin activation in elderly lymphocytes.
  6. 2020
    Comprehensive review of KEDA tetrapeptide and liver polypeptide complex (Ventvil) in age-related pathology models.
  7. 2023
    Most recent publication reviewing epigenetic modification of aged chromatin by peptide bioregulators including Livagen.
  8. Present
    No clinical trials registered. No FDA/EMA approval process initiated.

Sources & FAQs

Research sources(8)

Frequently asked questions(5)

What is Livagen and how does it work?

Livagen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Ala) developed by Russian scientist Vladimir Khavinson as a liver bioregulator. It works by loosening tightly packed DNA (chromatin) in aging cells, potentially reactivating genes that become silenced with age. It also protects natural pain-modulating molecules (enkephalins) from being broken down.

Is there strong clinical evidence for Livagen?

No. All evidence comes from laboratory cell studies and animal experiments, almost exclusively from Khavinson's research group. No controlled human clinical trials have been conducted. The research has not been independently replicated by Western laboratories.

Is Livagen safe?

No significant toxicity has been reported in the limited studies available, and no cytotoxic effects were observed in cell cultures. However, formal toxicology studies meeting international standards have not been conducted. There are no pharmacokinetic data, no reproductive toxicity assessments, and no long-term safety studies. The theoretical risk of sustained chromatin decondensation on genomic stability has not been explored.

Can I take Livagen orally?

One rat study reported weak digestive hydrolysis and biological effects after oral administration. Human oral bioavailability and any delivery advantage of injection remain unestablished.

How does Livagen compare to other Khavinson peptides like Epithalon?

Epithalon (AEDG) targets the pineal gland and has a somewhat larger research base, including some human observational data. Livagen (KEDA) specifically targets the liver and chromatin remodeling. Both share the ability to induce chromatin decondensation but in different tissue contexts. Neither has undergone rigorous controlled clinical trials.